特朗普单方面宣布这一关税100%，欧美贸易协议再陷混乱

Core Points - The European Commission has agreed to set a 15% cap on drug tariffs for American pharmaceuticals, providing protection for European companies [1] - President Trump announced a 100% tariff on all imported brand-name or patented drugs starting October 1, disrupting the recently established EU-US drug tariff agreement [1][3] - Trump stated that companies that have begun drug production investments in the US may qualify for exemptions, potentially benefiting European pharmaceutical giants like Roche, Novartis, and AstraZeneca [1] Group 1 - The EU and US had previously agreed to a unified 15% tariff, excluding generics, but Trump's actions are seen as a violation of this agreement and lacking legal basis [3] - The Brussels-based Innovative Pharmaceutical Group criticized Trump's repeated actions for undermining policy stability and emphasized the need for a focus on reasonable ways to share global R&D costs without harming patient interests [3] - Analysts suggest that Trump is using tariffs as a political tool to force concessions from other countries and raise drug prices, which threatens the EU pharmaceutical industry and directly impacts patient affordability [3] Group 2 - The Belgian Pharmaceutical Association expressed anticipation for the EU's response to Trump's tax announcement, stating that it violates the EU-US agreement and could significantly impact multiple EU countries, including Belgium [3] - The current uncertainty is putting pressure on investment decisions in Europe [3]